EA201291234A1 - Аналоги глюкагона - Google Patents

Аналоги глюкагона

Info

Publication number
EA201291234A1
EA201291234A1 EA201291234A EA201291234A EA201291234A1 EA 201291234 A1 EA201291234 A1 EA 201291234A1 EA 201291234 A EA201291234 A EA 201291234A EA 201291234 A EA201291234 A EA 201291234A EA 201291234 A1 EA201291234 A1 EA 201291234A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
gluacagona
analogue
glucagon
glp
Prior art date
Application number
EA201291234A
Other languages
English (en)
Inventor
Дитте Рибер
Эдди Мейер
Original Assignee
Зилэнд Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630046&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291234(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зилэнд Фарма А/С filed Critical Зилэнд Фарма А/С
Publication of EA201291234A1 publication Critical patent/EA201291234A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В изобретении предложены материалы и способы стимуляции снижения массы тела или предотвращения увеличения массы тела, а также для лечения диабета и связанных метаболических расстройств. В частности, в настоящем изобретении предложены новые пептидные соединения - аналоги глюкагона, эффективные для применения в таких способах. Эффект указанных пептидов может быть опосредован, например, повышенной селективностью в отношении рецептора GLP-1 по сравнению с глюкагоном человека.
EA201291234A 2010-06-24 2011-06-24 Аналоги глюкагона EA201291234A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201000558 2010-06-24
US35861410P 2010-06-25 2010-06-25
PCT/DK2011/000072 WO2011160633A1 (en) 2010-06-24 2011-06-24 Glucagon analogues

Publications (1)

Publication Number Publication Date
EA201291234A1 true EA201291234A1 (ru) 2013-07-30

Family

ID=44630046

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291234A EA201291234A1 (ru) 2010-06-24 2011-06-24 Аналоги глюкагона

Country Status (20)

Country Link
US (2) US9169310B2 (ru)
EP (1) EP2585482B1 (ru)
JP (1) JP6023048B2 (ru)
KR (1) KR20130086343A (ru)
CN (1) CN103068841A (ru)
AP (1) AP2013006671A0 (ru)
AU (1) AU2011269430A1 (ru)
BR (1) BR112012033225A2 (ru)
CA (1) CA2802897A1 (ru)
CL (1) CL2012003641A1 (ru)
CO (1) CO6660483A2 (ru)
EA (1) EA201291234A1 (ru)
EC (1) ECSP12012357A (ru)
MA (1) MA34383B1 (ru)
MX (1) MX2012014961A (ru)
NZ (1) NZ604208A (ru)
PE (1) PE20130338A1 (ru)
SG (1) SG186764A1 (ru)
TN (1) TN2012000560A1 (ru)
WO (1) WO2011160633A1 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
MY160219A (en) 2008-12-15 2017-02-28 Zealand Pharma As Glucagon analogues
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
JP5739526B2 (ja) 2010-06-24 2015-06-24 武田薬品工業株式会社 ホスホジエステラーゼ（ＰＤＥｓ）阻害薬としての縮合複素環化合物
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
AR091866A1 (es) 2012-07-23 2015-03-04 Zealand Pharma As Analogos del glucagon
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
ES2688708T3 (es) 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
WO2015193378A1 (en) * 2014-06-18 2015-12-23 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
WO2016055610A1 (en) * 2014-10-10 2016-04-14 Novo Nordisk A/S Stable glp-1 based glp-1/glucagon receptor co-agonists
JP6898231B6 (ja) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐアゴニスト化合物及び方法
FI3258919T4 (fi) 2015-02-17 2023-02-09 Nasaalinen jauheformulaatio hypoglykemian hoitoon
CA2979950A1 (en) 2015-03-18 2016-09-22 Zealand Pharma A/S Amylin analogues
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AU2016247499B2 (en) 2015-04-16 2020-09-03 Zealand Pharma A/S Acylated glucagon analogue
SG11201811804QA (en) 2016-08-05 2019-01-30 Boehringer Ingelheim Int Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
KR102502040B1 (ko) * 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
KR102230363B1 (ko) * 2017-08-16 2021-03-22 동아에스티 주식회사 아실화 옥신토모듈린 펩타이드 유사체
MX2020008116A (es) 2018-02-02 2020-09-25 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP3746443B1 (en) 2018-02-02 2022-07-06 Boehringer Ingelheim International GmbH Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CN111630055B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
BR112020013082A2 (pt) 2018-02-02 2020-12-01 Boehringer Ingelheim International Gmbh derivados de oxadiazolopiridina benzil-, (piridin-3-il)metil- ou (piridin-4-il)metil- substituídos como inibidores de grelina o-acil transferase (goat)
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CA3185637A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
WO2023016346A1 (zh) * 2021-08-10 2023-02-16 南京明德新药研发有限公司 含内酰胺桥的多肽化合物
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
WO1998011126A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
PT929567E (pt) 1996-09-09 2005-07-29 Zealand Pharma As Sintese em fase solida de peptidos
UA65549C2 (ru) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
AU3273500A (en) 1999-03-17 2000-10-04 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
SK2432004A3 (sk) 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2518776A1 (en) 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
PT1891105E (pt) 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
EP1959986B1 (en) 2005-11-07 2014-07-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
EP1991574B1 (en) 2006-02-22 2016-10-12 Merck Sharp & Dohme Corp. Oxyntomodulin derivatives
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
EP2074140B8 (en) 2006-10-04 2015-10-28 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
NZ588857A (en) 2008-04-22 2012-07-27 Univ Case Western Reserve Isoform-specific insulin analogue for control blood sugar levels
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
EA019203B9 (ru) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты глюкагонового рецептора/glp-1-рецептора
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
ES2552636T3 (es) 2008-07-31 2015-12-01 Case Western Reserve University Insulina estabilizada por halógenos
MY160219A (en) 2008-12-15 2017-02-28 Zealand Pharma As Glucagon analogues
WO2010070252A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
CN102256992B (zh) 2008-12-19 2015-04-22 印第安纳大学研究及科技有限公司 胰岛素类似物
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
EA022816B1 (ru) * 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
EP2665487A1 (en) 2011-01-20 2013-11-27 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
US20130316941A1 (en) 2011-12-23 2013-11-28 Boehringer Ingelheim International Gmbh Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
ES2688708T3 (es) 2013-10-17 2018-11-06 Zealand Pharma A/S Análogos de glucagón acilados

Also Published As

Publication number Publication date
BR112012033225A2 (pt) 2017-06-20
JP2013530969A (ja) 2013-08-01
EP2585482A1 (en) 2013-05-01
MA34383B1 (fr) 2013-07-03
EP2585482B1 (en) 2019-03-27
CN103068841A (zh) 2013-04-24
NZ604208A (en) 2014-10-31
US9169310B2 (en) 2015-10-27
SG186764A1 (en) 2013-02-28
AU2011269430A1 (en) 2013-01-10
TN2012000560A1 (en) 2014-04-01
CO6660483A2 (es) 2013-04-30
WO2011160633A1 (en) 2011-12-29
KR20130086343A (ko) 2013-08-01
JP6023048B2 (ja) 2016-11-09
US20130157929A1 (en) 2013-06-20
CL2012003641A1 (es) 2013-09-06
MX2012014961A (es) 2013-02-26
PE20130338A1 (es) 2013-03-16
CA2802897A1 (en) 2011-12-29
ECSP12012357A (es) 2013-01-31
AP2013006671A0 (en) 2013-01-31
US20150376257A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
EA201291234A1 (ru) Аналоги глюкагона
EA201291233A1 (ru) Аналоги глюкагона
EA201290027A1 (ru) Ацилированные аналоги глюкагона
PH12015500531A1 (en) Glucagon analogues
PH12016500675B1 (en) Acylated glucagon analogues
EA201190048A1 (ru) Аналоги глюкагона
EA201190054A1 (ru) Аналоги глюкагона
EA201190047A1 (ru) Аналоги глюкагона
EA201190049A1 (ru) Аналоги глюкагона
EA201490982A1 (ru) Аналоги глюкагона
MX2016004907A (es) Analogos del glucagon.
MX2017012864A (es) Analogo acilado del glucagon.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201591839A1 (ru) Терапевтические пептиды
TN2011000667A1 (en) Acylated glucagon analogues
CY1116448T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
ECSP15009978A (es) Análogos de glucagón
CO6382136A2 (es) Análogos de glucagón